Logo image
Back
Office‐based vergence and anti‐suppression therapy for the treatment of small‐to‐moderate angle intermittent exotropia: A randomised clinical trial
Journal article   Open access   Peer reviewed

Office‐based vergence and anti‐suppression therapy for the treatment of small‐to‐moderate angle intermittent exotropia: A randomised clinical trial

Martin Ming‐Leung Ma, Ying Kang, Mitchell Scheiman, Qiwen Chen, Xuelian Ye, Liuqing Pan, Jiayu Deng, Guangxing Su, Guohui Zhang and Xiang Chen
Ophthalmic & physiological optics, v 44(2), pp 356-377
Mar 2024
DOI: https://doi.org/10.1111/opo.13264
PMID: 38146812
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1111/opo.13264View
Published, Version of Record (VoR) Open

Abstract

Abstract Purpose To evaluate the short‐term (1 week after completion of treatment) effect of office‐based vergence and anti‐suppression therapy (OBVAT) on the Office Control Score when compared to observation alone in children with small‐to‐moderate angle intermittent exotropia (IXT). Methods In this single‐masked (examiner masked), two‐arm, single‐centre randomised clinical trial, 40 participants, 6 to <18 years of age with untreated IXT, were randomly assigned to OBVAT or observation alone. Participants assigned to therapy received 60 min of OBVAT with home reinforcement once per week for 16 weeks. Therapy included vergence, accommodation and anti‐suppression techniques. The primary outcome measure was the comparison of the distance Office Control Score between the two groups at the primary outcome visit (i.e., 17‐week follow‐up visit). Results At the primary outcome visit, the OBVAT group ( n  = 20) had a significantly better distance Office Control Score (adjusted mean difference: −0.9; 95% CI: −0.2 to −1.5; p  = 0.008; partial eta squared: 0.19) than the observation group ( n  = 16). Participants from the OBVAT group were more likely than those from the observation group to have ≥1 point of improvement at the 17‐week visit (OBVAT group: 75%; Observation group: 25%; p  = 0.006). Conclusions In this randomised clinical trial of participants aged 6 to <18 years with IXT, we found that the OBVAT group had a significantly better distance Office Control Score than the observation group at the 17‐week visit. This study provides the first data from a randomised clinical trial demonstrating the effectiveness of OBVAT for improving the control of IXT. Eye care practitioners should consider OBVAT as a viable, non‐surgical treatment option for IXT. A full‐scale randomised clinical trial investigating the long‐term effectiveness of OBVAT in treating IXT is warranted.

Metrics

7 Record Views
4 citations in Web of Science
4 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
International collaboration
Web of Science research areas
Ophthalmology
Logo image